Search

everythinglearnresearchcommunity

for

Search:↓

Filgotinib completely reversed hair loss in a patient with rheumatoid arthritis and alopecia universalis.

Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.

Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.

Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.

Dupilumab improves skin microbiome balance in atopic dermatitis patients.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

Rituximab may cause skin issues, but baricitinib can help improve them.

Dupilumab helped a 4-year-old grow hair back after another treatment failed.

Baricitinib successfully treated myasthenia gravis and alopecia in a patient.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

Combining glucocorticoids with immunosuppressants like cyclophosphamide improves remission and reduces relapse in pemphigus patients.

Higher monocyte counts predict less effective adalimumab treatment in hidradenitis suppurativa patients.

Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.

Bimekizumab effectively treated a man's chronic beard hair loss.

Immunoadsorption successfully treated a man's resistant polymyositis.

IL-12/23 inhibitors are more effective and have fewer common side effects than anti-TNF alpha for treating psoriasis.

The targeted nanohybrids effectively reduced psoriasis symptoms and improved skin health.

Ixekizumab is safe for long-term use with low rates of major heart-related events.

Anifrolumab improves quality of life and reduces steroid use in SLE patients.

Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

A comprehensive approach to educating patients and managing side effects is crucial for improving adherence to multiple sclerosis treatments and patient quality of life.

Anifrolumab effectively improved lupus headaches in a patient unresponsive to other treatments.

Dupilumab treatment reduces Th2-related markers and helps hair growth in alopecia areata, showing Th2's role in the condition.

A woman with bullous pemphigoid had an allergic reaction to azathioprine, but got better with alternative treatments.

Anifrolumab improves quality of life and reduces steroid use in lupus patients.

Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.